HELSINN GROUP AND EISAI INC. ANNOUNCE START OF PHASE III CLINICAL PROGRAM OF ORAL FIXED-DOSE COMBINATION OF NETUPITANT/ PALONOSETRON (300 mg/0.50 mg) FOR PREVENTION OF CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV)